Importin-mediated transport of cargoes is known to be a key mechanism for nucleo-cytoplasmic trafficking of molecules. Ipo13, which is a member of Importin-β gene family, encodes two transcripts by utilizing different transcription start sites. In the mouse, the full-length transcript (L-Ipo13) is expressed in the primordial germ cells in the embryo and is later expressed predominantly at the pachytene phase of meiosis in both male and female germ cells. The shorter transcript (TS-Ipo13) is only expressed in the germ cells in the adult testis. Activity of L-Ipo13, but not TS-Ipo13, mediates the nuclear accumulation of ubiquitin-conjugating enzyme 9 (UBC9), a cargo of human IPO13. This finding is consistent with the progressive accumulation of UBC9 in the nucleus of the meiotic germ cells after the onset of L-Ipo13 expression. Following siRNA knockdown of IPO13 activity in the fetal ovary, fewer germ cells are found to progress to the late-pachytene stage of meiosis and nuclear accumulation of UBC9 is reduced. Our findings strongly implicate a stage-specific role of IPO13 in nuclear-cytoplasmic translocation of cargoes that accompanies meiotic differentiation of the mouse germ cells.
Introduction
Germ cells are unique in their capacity to undergo meiotic division and the differentiation into gametes that on fertilization enables the transmission of genetic materials between generations. In mice, female germ cells enter the prophase of meiotic division at around Embryonic (E) day 13.5 and reach the pachytene stage at E15.5-19.5. In the fetal testis, the germ cells enter mitotic arrest on E13.5 and recommence proliferation after birth. In the neonatal (Day 10) testis, spermatogonia differentiate into resting spermatocytes, some of which undergo meiosis and reach early pachytene stage of meiotic prophase at Day 12.
Importin13 (Ipo13) is identified in a subtractive screening of cDNA to be differentially expressed in the migrating E8.5-9.5 mouse primordial germ cells (PGCs) (Tanaka and Matsui, 2002) . Ipo13 is one of 22 known members of importin-β like gene family, which encodes transporters that act as the shuttle of cargoes between the nucleus and the cytoplasm (Strom and Weis, 2001; Weis, 2003) . The regulation of nucleo-cytoplasmic trafficking of cargo molecules is crucial for cell functions, such as the cell cycle progression and proliferation, and the transduction of signaling activities (Yoneda, 2000; Weis, 2003) . Rat Ipo13 was identified in a search for glucocorticoid-inducible genes. It is expressed in the epithelium of the fetal lung at the pseudoglandular stage of organogenesis (Zhang et al., 2000) . Human IPO13 acts both as importer and exporter Developmental Biology 297 (2006) 350 -360 www.elsevier.com/locate/ydbio of cargoes: It mediates the nuclear import into the nucleus of ubiquitin-conjugating enzyme 9 (UBC9), RNA-binding motif protein 8 (RBM8), and human homologue of Drosophila mago nashi protein (MGN), and export from the nucleus of eukaryotic translation initiation factor 1A protein (eIF1A) under the influence of Ran-GTP activity (Mingot et al., 2001) . In this study, we have characterized two transcripts of mouse Ipo13. A full-length (long) transcript, L-Ipo13, and a testis specific shorter transcript, TS-Ipo13, are produced via the utilization of different transcription start sites. We further showed that L-Ipo13 is expressed predominantly in germ cells at the pachytene stage of meiotic prophase I in addition to its expression in migratory PGCs. Down-regulation of IPO13 by RNA delays the progression through prophase I of meiosis in oocytes and reduces nuclear accumulation of UBC9. During spermatogenesis, the nuclear localization of UBC9 protein succeeds the expression of the transcription of the L-Ipo13 mRNA. We showed that in GC1 cells derived from spermatogenic cells, enforced expression of L-Ipo13 but not TS-Ipo13 leads to nuclear import of UBC9 protein. Together, these results suggest that IPO13 is a key transporter of cargo molecules which may regulate the progression of meiosis during gametogenesis.
Materials and methods

Northern blot
Total RNA was extracted by using either RNeasy (QIAGEN) or ISOGEN (Nippongene) from several tissues (testis, ovary, brain, liver and kidney) of adult mice of more than 8 weeks old, and from male and female gonads of the fetus and mice of neonatal ages. Northern blot was performed using 20 μg of total RNA of adult tissues, and 10 μg of total RNA of ovaries and testes per sample. The genomic regions that correspond to positions of the Northern probes, cDNA clone #B94, the L-probe for L-Ipo13 mRNA and C-probe for both L-Ipo13 and TS-Ipo13 mRNA were shown in Fig. 1A .
RT-PCR
Reverse transcription was carried out using Superscript II (Invitrogen) with 1 μg total RNA (fetal and adult gonads). PCR amplification was performed using either Ex-taq system (Takara) or Taq DNA Polymerase (Roche). PCR amplifications were performed with 25 cycles for Hprt, 35 cycles for L-Ipo13 and 45 cycles for TS-Ipo13 of 1 min at 94°C, 1 min at 60°C, and 1 min at 72°C, respectively. Sequences of the primer sets for PCR amplification are listed below and the corresponding genomic positions are shown in Fig. 1A .
L-Ipo13, L1: 5-′catggcatctgccgtattgc-3′ and L2: 5′-tgcatcagccacatgcactg-3′. TS-Ipo13, TS1: 5′-atcctgattccctctgccctc-3′ and TS2: 5′-gcaggttcttcaggatctcc-3′.
Hprt, 5′-ggatttgaaattccagacaag-3′ and 5′-gcatttaaaaggaactgttgac-3′.
Rapid amplification of cDNA ends (RACE)
5′ and 3′ RACE were performed by using Marathon cDNA amplification kit according to the manufacturer's instruction (Clontech). First strand cDNAs were synthesized from a poly(A) RNA, which was purified using Oligotex-dT30 (Roche) from adult testis total RNA. To confirm the expression of two RACE products as intact transcripts, end-to-end RT-PCR was carried out with L-Ipo13 or TS-Ipo13 specific primer sets. Sequences of the primer sets are listed below and the corresponding genomic positions are shown in Fig. 1A .
L-Ipo13, L3: 5′-agatggagcggcgggaggag-3′ and L4: 5′-ctcagtagtcagctgtgtag-3′. TS-Ipo13, TS1: 5′-atcctgattccctctgccctc-3′ and L4: 5′-ctcagtagtcagctgtgtag-3′.
Sample preparation for in situ hybridization and histochemistry
Embryos were collected from pregnant mice of ICR × B6D2F1 or ARC/S strain. The use of animal is approved by the Animal Care and Ethics Committee (ACEC) of the Children's Medical Research Institute and the Children's Hospital at Westmead under ACEC project 138. E9.5 to 20.5 embryos were dissected in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% calf serum or in Phosphate-buffered (PB)-1 medium. Embryos and adult tissues were fixed with 4% paraformaldehyde (PFA) in phosphate buffer saline (PBS). Testes were collected from adult mice that were anaesthetized and perfused by 4% PFA in PBS for fixation of tissues. After dehydration in graded ethanol-series, tissue specimens were cleared in xylene and embedded in paraffin (Paraplast; Oxford labware), and 10 μm sections were prepared for in situ hybridization and immunohistochemistry.
In situ hybridization
Procedure for in situ hybridization was described by Wilkinson (1992) . Either biotin or digoxigenin (Roche) labeled riboprobes were used. The riboprobes were 1.3 kb full-length cDNA for detection of Pou5f1 (Oct-3/4), a 503 bp cDNA spanning in ORF of germ-cell-specific Ddx4 (Mvh) (Fujiwara et al., 1994) , and L-Ipo13-specific L-probe and C-probe which recognizes both L-Ipo13 and TS-Ipo13 transcripts ( Fig. 1A ).
Immunohistochemistry
For the immunostaining of UBC9 in the germ cells, 10-μm paraffin sections of adult testis and fetal ovary were incubated with retrieval solution according to the manufacturer's instructions (pH 6.0, DAKO). After treatment with 0.3% Boehringer blocking reagent (BBR; Roche), sections were incubated with 1/ 250 dilution of anti-UBC9 mouse monoclonal antibody (Pharmingen) in 0.1% BBR at 4°C for 16 h. Detection was done by ABC staining kit according to manufacturer's instructions (Vector Laboratories). For immunostaining of germ cells in cultured and intact fetal ovaries, the specimens were fixed with 4% PFA and embedded in OCT compound (Tissue-Tek). Frozen 10-μm-thick sections were prepared by Cryostat, and treated with 1/200 dilution of anti-SCP3 rabbit monoclonal antibody (Chuma and Nakatsuji, 2001) . The sections were then treated with Alexa594-tagged anti-rabbit secondary antibody at 1/1000 dilution (Molecular Probe), followed by DAPI (SIGMA) staining. Immunostaining of Myc-tagged fusion-protein was done using anti-MYC antibody at 1/250 dilution (SIGMA) and Alexa594-tagged anti-mouse secondary antibody at 1/750 dilution (Molecular Probe).
Fluorescence and confocal microscopy
Fluorescence imaging was performed using an Olympus BX51. Results of anti-UBC9 immunostaining in testes were recorded using Nikon OPTIPHOT-2 microscope. Confocal microscopy for the detection of whole mount in situ hybridization signals in embryos was done using the Leica DMRB/E and Leica SP2 confocal scanning system.
Enforced expression of IPO13 in GC1 cells
Expression vectors were comprising of a CMV-promoter and an IRES-EGFP expression vector (pIRES-EGFP; Clontech; also used as a control vector) into which sequences coding for full size IPO13 protein (pCMV-L-Ipo13-FLAG-IRES-EGFP) or the short isoform of IPO13 (pCMV-TS-Ipo13-FLAG-IRES-EGFP) were incorporated. Open reading frames of either L-Ipo13 or TS-Ipo13 were amplified by RT-PCR and fused in frame to a FLAG-tag at the C-terminal end, then inserted into the multi-cloning site of pIRES-EGFP. Construction of pCI-Ubc9-Myc expression vector was described by Machon et al. (2000) . GC1 cells were cultured in DMEM containing 10% FCS on a four-well chamber slide (NUNC). Expression vectors of IPO13 and UBC9 were lipofected using Lipofectamine 2000 transfection reagent (QIAGEN), according to manufacturer's instructions. About 6 h after transfection at 37°C, cells were fixed with 4% PFA to examine the distribution of UBC9-MYC fusion-protein in the cells.
In vitro culture and siRNA treatment of the fetal ovary
Results of a preliminary study on the efficiency of introducing EGFP expression construct by lipofection showed that a more consistent outcome was achieved for fetal ovary than neonatal testes. The down-regulation of L-Ipo13 activity on the progression of meiosis was therefore performed on the E15.5 fetal ovary. E15.5 ovaries were sliced open and immersed for 2 min in a liposome solution containing one of the three siRNA reagents: siRNA#1, siRNA#2 or scrambled sequence (QIAGEN) prepared as per RNAiFect methods (QIAGEN). The sequence of the siRNA construct and the targeted Ipo13 sequences are: siRNA#1: ccgaccagtatgaaagcttaa targeted to 913-933 bp (NM_146152), siRNA#2: cacggactacacagctgacta to 3497-3517 bp (NM_146152), and scrambled sequence control: aattctccgaacgtgtcacgt. The 3′ end of the sense sequence of each construct was tagged with Alexa488 green Fluorescent dye (QIAGEN). The treated ovaries were cultured for 3 days on 0.3 μm of isopore membrane filters (Millipore) floating on DMEM with 20% FCS in 5% CO 2 in air at 37°C (Park and Taketo, 2003) . Staging of oocytes in the cultured ovaries was done based on the DAPI staining and anti-SCP3 immunostaining patterns of the frozen sections. The efficiency of Ipo13 knockdown was assessed by Western blot analysis using the anti-IPO13 rabbit antibody against IPO13 peptides (RERVNKRRVKEMVK, Hokkaido System Science Co.) or by RT-PCR. Both anti-IPO13 and anti-FLAG antibodies detected a same 92 kDa band in pCMV-IPO13-FLAG-IRES-eGFP lipofected STO cells (data not shown). For Western blot analysis, the detection of IPO13 protein in the treated ovaries was performed by anti-IPO13 primary antibody (1:500) and horseradish peroxidase conjugated secondary antibody (1:10000; Bio-Rad) according to manufacturer's instructions.
Results
Cloning of germ-line-specific mouse Importin13 orthologue
A cDNA clone #B94, which encoded a 308 bp partial sequences of mouse Importin13 gene (Ipo13, accession number; NM_146152, Fig. 1A ) was identified by subtractive screening of the cDNA prepared from migratory PGCs (E8.5-9.5) and E3.5 blastocysts ( Fig. 1B ; Tanaka and Matsui, 2002) . By RT-PCR analysis, Ipo13 is found to be expressed in the hindgut and fetal gonads but not in blastocysts (Fig. 1C ). Northern blot analysis using the #B94 fragment as a probe showed expression of 3.4 kb Ipo13 transcript predominantly in the adult testis, brain and the kidney (Fig. 1D ). In the adult testis, a 1.6-kb transcript, which was not discovered previously, is also expressed (Fig. 1D ).
To determine if the two mRNAs hybridized with the #B94 probe are different transcripts of Ipo13, 5′ and 3′ rapid amplification of cDNA ends (RACE) of #B94 fragment in testis sample was performed. Two products were obtained and the authenticity of those transcripts was confirmed by end-to-end RT-PCR (data not shown). The long product is found to be the full-length 3.4 kb transcript of the Ipo13 gene, whereas the short 1.6 kb product corresponds to a transcript containing 75 bp of 6th intron sequences and exons from 7th to 20th of the gene (Fig. 1A) , which is produced by using a transcriptional start site in 6th intron of Ipo13. These two Ipo13 mRNA are therefore named the long-form Ipo13 transcript (L-Ipo13) and the testisspecific short-form Ipo13 transcript (TS-Ipo13). The putative protein (about 92 kDa with 963 amino acids, IPO13) encoded by the L-Ipo13 transcript is conserved among mouse, human (99.2%) and rat (98.8%). The putative 438 amino acids protein (TS-IPO13) encoded by the TS-Ipo13 transcript is identical to the C-terminal fragment of IPO13 ( Fig. 1E ).
Expression of L-Ipo13 and TS-Ipo13 in the germ cells L-Ipo13 transcript is expressed in the gonad of the fetus, the neonatal (1 week old) and adult mice of both sexes ( Fig. 2A) . A significantly stronger signal is detected in the E17.5 fetal ovary and the adult testis. In contrast, TS-Ipo13 is detected only in the adult testis ( Fig. 2A ). The expression profile of L-Ipo13 and TS-Ipo13 was examined in a finer time scale in the testes of 1, 2, 3 weeks old and adult (more than 6 weeks old) mice to determine the stage when the strong Ipo13 expression commences. L-Ipo13 expression reaches the adult level at 3 weeks old testis, when many spermatocytes have reached the pachytene stage of prophase I of meiosis (Fig. 2B ). In contrast, TS-Ipo13 expression is first detected in the 4 weeks old testis (data not shown) and attains the strongest expression in the adult testis ( Fig. 2B) . A low level of expression of L-Ipo13 and no TS-Ipo13 transcripts are detected in the testis of the W/W v mutant mice ( Fig. 2A) . The faint expression of L-Ipo13 in the mutant testis may be related to the depletion, though not complete absence, of spermatogenic cells (Ohta et al., 2003) . These findings strongly suggest that L-Ipo13 is expressed specifically in the germ cells.
Expression of L-Ipo13 in the germ cells was further examined by double in situ hybridization of E9.5 embryos and E13.5 gonads using probes for L-Ipo13 and Pou5f1 (Oct-3/4). In E9.5 embryos, Ipo13 is expressed in the Pou5f1 positive PGCs in the hindgut (Figs. 3A-A′′). L-Ipo13 and Pou5f1 are also co-expressed in the germ cells of the male (Figs. 3B-B′′) and female E13.5 gonad (Figs. 3C-C′′).
Stage-specific expression of L-Ipo13 in meiotic germ cells
The pattern of expression of L-Ipo13 in the meiotic germ cells was examined by in situ hybridization on histological preparations of the adult testis and the fetal ovary. Using L-Ipo13-specific L-probe ( Fig. 1A) , strong expression of L- Ipo13 is revealed in the pachytene stage spermatocytes localized immediately next to the spermatogonia (Figs. 4B-B′ and C-C″), while non-specific signals are found in the outer spaces of seminiferous tubules using control sense probe (Figs. 4A-A′). Hybridization using the C-probe ( Fig.  1A) , which recognizes both L-Ipo13 and TS-Ipo13 transcripts, revealed no significant difference in the pattern of expression (data not shown). In the spermatocytes, localized signals for Ipo13 riboprobe can also be detected in the nucleus (Figs. 4B′, 4C′, 5D and F). L-Ipo13 is also expressed specifically in the To elucidate the stage when strong L-Ipo13 expression commences during oogenesis, RT-PCR was performed on the fetal ovaries of E13.5-20.5 embryos. Strongest expression of L-Ipo13 is detected at E17.5-19.5 ovary where pachytene germ cells are present, and by E20.5 the expression returns to the low E13.5 level (data not shown). L-Ipo13 therefore is expressed most strongly in male and female germ cells at the pachytene stage of meiosis I.
L-Ipo13 activity regulates intracellular localization of UBC9 protein
In human, IPO13 is reputed to regulate the nuclear localization of UBC9 (Mingot et al., 2001) . In the adult mouse testes, we found that UBC9 is localized in the nucleus of the spermatogenic cells in a stage-specific manner (Figs. 5A, B -B′ and C-Cʺ), which is consistent with the presence of UBC9 in the synaptonemal complexes (Kovalenko et al., 1996) . We examined if the expression of L-Ipo13 may coincide with the nuclear localization of UBC9 in the meiotic germ cells. In the pachytene stage spermatocytes that express L-Ipo13 transcripts (Figs. 5D and F), UBC9 protein is widely distributed in the cytoplasm (Figs. 5E and F′-Fʺ, white arrows) in the stage V seminiferous tubule. UBC9 shows nuclear localization characteristically in the round spermatids that have down-regulated L-Ipo13 expression (Figs. 5F-Fʺ, black arrows). These results show that elevated expression of L-Ipo13 in the pachytene stage spermatocytes precedes the nuclear accumulation of the UBC9 protein (Fig. 5G) .
To further elucidate if IPO13 mediates nuclear import of UBC9 protein, the distribution of UBC9-MYC fusion protein was examined in GC1 cell (which were derived from spermatogenic cells; Hofmann et al., 1992 ) that expressed L-Ipo13-IRES-GFP. In cells that expressed IPO13 protein ( Fig. 5H  aʺ) , UBC9-MYC fusion protein was localized predominantly in the nucleus (Fig. 5H a, a′, white arrows, see legend for further details). In contrast, UBC9-MYC protein was not localized to the nucleus of GC1 cells that expressed the TS-IPO13 protein (Fig. 5H b-bʺ, white arrowhead) and in cells that expressed only the IRES-GFP construct (Fig. 5H c-cʺ, white arrowheads) . No proteins containing epitope that cross-reacts with the anti-MYC antibody were detected in GC1 cells expressing only the GFP (Fig. 5H d-dʺ ), suggesting that the immunoreactive protein detected in the IPO13 and TS-IPO13 expressing cell is the UBC9-MYC fusion protein. The expression pattern of L-Ipo13 and UBC9 in the primary spermatocytes in vivo and the effect of L-Ipo13 expression on the sub-cellular localization of UBC9 in the GC1 cells suggest that IPO13 protein influences the nuclear accumulation of UBC9 in the germ cells.
Down-regulation of L-Ipo13 in female germ cell impedes the progression of meiosis
The role of IPO13 in germ cell differentiation was examined by siRNA (short interference RNA) knockdown of Ipo13 activity in the fetal ovaries cultured in vitro. In the fetal ovary treated with siRNA with scrambled sequence tagged by Alexa488 at E15.5 and cultured for 3 days in vitro, about 80% (range: 60-95%) of the Alexa488 positive oocytes (Fig.  6A a-c) were also stained positively with anti-SCP3 (synaptonemal complex protein 3) antibody (Fig. 6A d) . This finding shows that the transfection and culture procedures are efficient and have no impact on the meiotic differentiation of the oocytes.
Two siRNA constructs were used; siRNA#1 and siRNA#2, which are directed to different sequences of the L-Ipo13 mRNA (Fig. 1A) . Both reagents were effective in the knockdown of IPO13: The amount of IPO13 protein was significantly reduced in the siRNA-treated ovary when compared to that in fetal ovaries treated with siRNA comprising of a scrambled sequence (SS) (Fig. 6B a, b) . Consistent with this result, RT-PCR analysis also demonstrated that Ipo13 expression level was reduced in siRNA-treated ovary ( Fig. 6B c, d) .
To confirm the impact of Ipo13 knockdown on the trafficking of UBC9, we examined the nuclear localization of UBC9 in the siRNA-treated oocytes. The results showed that UBC9 protein is localized to the nucleus of 92.5% of the SStreated oocytes (n = 40; Fig. 6C a and a′) . In contrast, only 67.9% of the siRNA#1 and #2 treated oocytes (n = 56) show nuclear localization of UBC9 ( Fig. 6C b and b′) , indicating that about 32% of the treated oocytes failed to transport the cargo due to the down-regulation of IPO13 (significant difference at P < 0.01 by Chi squared test).
To determine the impact of IPO13 knockdown on meiosis, we have examined the relative frequency of meiotic oocytes at different stages of meiotic prophase I in the siRNA treated fetal ovary. Staging of oocyte was done based on the nuclear morphology (revealed by DAPI staining) and the synaptonemal complex (anti-SCP3 staining pattern) (Schalk et al., 1998; McClellan et al., 2003; Park and Taketo, 2003) . The Zygotene/Pachytene (Zy/Pa) stage oocytes have irregularly shaped nucleus, and thick and long strands of synaptonemal complex on the condensed chromatid ( Fig. 6D Zy/Pa) . The mid-pachytene (M-Pa) and late-pachytene (L-Pa) oocytes are identified by the spherical and enlarged nuclei. The M-Pa oocytes show decondensing chromatids which are still decorated with strands of SCP3-positive synaptonemal complex (Fig. 6D M-Pa) , whereas the L-Pa oocytes show more extensively de-condensed chromatids and clumping of SCP3-positive material (Fig. 6D L-Pa) . The Pachytene/Diplotene (Pa/Di) stage oocytes have large and spherical nucleus containing completely de-condensed chromatids and one to two clumps of anti-SCP3 antibody stained material ( Fig. 6D Pa/Di) .
In the E15.5 fetal ovary collected at the beginning of the in vitro culture experiment, all oocytes are at the Zy/Pa stage (Fig.  6D E15.5 in vivo) . In the E18.5 fetal ovary (Fig. 6D E18 .5 in vivo), the oocytes are at different stages of prophase of meiosis I: 6.1% at Zy/Pa, 40.8% at M-Pa, 20.4% at L-Pa and 32.7% at Pa/Di (Fig. 6D ). In the untransfected (Fig. 6D not transfected) or siRNA treatment control (Fig. 6D SS; scrambled sequence) ovaries cultured from E15.5 for 3 days in vitro to the equivalent age of E18.5, the distribution of oocytes to the four meiotic prophase I stages were not different from the E18.5 fetal ovary ( Fig. 6D E18 .5 in vivo), suggesting that the in vitro culture condition supports normal progression of meiosis, and the lipofection of exogenous RNA have no adverse effect on the differentiation of the oocytes. In marked contrast, fetal ovary treated with either siRNA#1 or siRNA#2 and cultured for the same period after treatment contained about 50% fewer L-Pa stage oocytes that were transfected with the siRNA tagged by the Alexa488. There was a concurrent increase in the proportion of M-Pa oocytes among the meiotic germ cells (Fig. 6D  siRNA#1; siRNA#2) . Knockdown of Ipo13 activity therefore impedes the progression of meiosis to the L-Pa phase in about 10-11% of the oocytes. Our finding therefore implicates a role of IPO13 in regulating the progression through the pachytene stage of prophase I of meiosis.
Discussion
Expression of Importin13 accompanies the progression through the pachytene stage of meiosis during gametogenesis
In general, Importin-β family genes are not known to be expressed in lineage-or stage-specific pattern. Here, our study of L-Ipo13 in the mouse showed that L-Ipo13 is expressed in the migratory PGCs and in the germ cells that colonize the E13.5 fetal gonad of both sex. L-Ipo13 expression is elevated in the E17.5 fetal ovary when the germ cells enter into meiosis, and the expression is detected specifically in the pachytene stage oocytes. The elevated expression is detected at E17.5-19.5 ovary where pachytene germ cells are present. In the male mouse, L-Ipo13 is strongly expressed in the spermatocytes as they enter into the pachytene stage of the prophase I of meiosis and is down-regulated in germ cells past the pachytene stage in adult testis.
The temporal relationship of the stage-specific expression of L-Ipo13 in the pachytene stage primary spermatocytes and primary oocytes is consistent with a role of IPO13 in the regulation of progression of the prophase I of meiosis during gametogenesis. In Drosophila, several Importins are expressed in successive stages of spermatogenesis (Giarre et al., 2002) : Importin-α2 is expressed in the spermatogenic cell spanning the spermatogonial stage to the end of second meiotic division. Importin-α1 is expressed in the germ cells till they differentiate into early spermatids and Importin-α3 is expressed in post-meiotic cysts. Loss of function of Importin-α2 blocks spermatogenesis, and leads to the production of defective sperm and male sterility (Giarre et al., 2002; Gorjanacz et al., 2002; Mason et al., 2002) . The sterility could be rescued by reconstituting Importin-α2 activity or by expressing Importin-α1 or -α3 (Mason et al., 2002) , pointing to a functional overlap of these three Importins. In C. elegans, Importin-α1, -α2 and -α3 are successively expressed in germ line cells (Geles and Adam, 2001) . Specifically, RNAi experiments demonstrate that Importin-3α protein is required for the progression of meiotic prophase I during oocyte development (Geles and Adam, 2001) . A compelling indication of the critical function of IPO13 in the progression of prophase I of meiosis is shown by the delay in the transition from mid-to late-pachytene of female germ cells in the Ipo13-siRNA treated fetal mouse ovaries.
The two forms of Importin13 protein may have different functions in spermatogenesis Members of Importin-β family are known to mediate the import and export of molecular cargoes between the nucleus and the cytoplasm in response to a graded GTPase activity of Ras-related nuclear protein (Ran-GTPase). RanGTP activity which regulates the kinetics of binding and release of the cargoes is mediated by the activity of the RanGTP-binding domains in the N-terminal part of the Importin-β protein. The response to Ran-GTPase activity leads to the coupling of Importing with the cargo via the carboxy-terminal domain (Strom and Weis, 2001) . Consistent with this concept, protein pull-down assay has revealed that rat IPO13 protein is coupled to the functional RanGTP-binding domain in the N-terminal amino acids 1-488 fragment, but not in the C-terminal 489-963 amino acids fragment (Tao et al., 2004) .
We showed in the present study that mouse Ipo13 codes for two transcripts: a full-length L-Ipo13 mRNA, and a shorter TS-Ipo13 mRNA that contains sequences of part of intron 6 and Russell et al. (1990) . (H) In L-Ipo13-IRES-EGFP transfected GC1 cells (a′′), UBC9-MYC (produced by expression of the pCMV-Ubc9-Myc construct) is accumulated preferentially in the nucleus (a, a′; white arrows in a′). About 50% of the GFP-positive cells showed nuclear localization of UBC9-MYC and the remaining showed both nuclear and cytoplasmic localization. No GFP-expressing cells were found to display only cytoplasmic distribution of UBC9-MYC. In contrast, expression of TS-Ipo13 (b′′) did not lead to any nuclear accumulation of UBC9 (b, b′; white arrowhead in b′). The UBC9 protein (c) does not show any nuclear accumulation (white arrowheads in c′) when the cells were transfected with the IRES-GFP construct (c′′) . No other molecules containing the epitope that may be recognized by the anti-MYC antibody was detected (d, d′) in cells expressing only the IRES-GFP construct (d′′). a-d: red immunofluorescence with anti-MYC antibody; a′-d′: DAPI staining for the nucleus merged with a-d; a′′-d′′: GFP expression in transfected cells merged with a′-d′. Three replicate experiments were performed, and between 60 and 70 cells were scored in total for each of the four transfection-types. Scale bar: 10 μm.
those of exons 7-20. The L-Ipo13 mRNA and protein are expressed in both the male and female pachytene meiotic germ cells, but the TS-Ipo13 mRNA is only expressed in the spermatogenic cells.
The putative peptide encoded by TS-Ipo13 transcript lacks the RanGTP-binding domain encoded by the N-terminal exon 1-6 sequences of the full-length L-Ipo13 transcript. TS-IPO13 might therefore be unable to respond to RanGTP activity due to the absence of binding domain for RanGTP. Enforced expression of L-IPO13 in the GC1 cells is accompanied by the nuclear localization of the UBC9 protein, whereas the expression of TS-Ipo13 is unable to elicit any nuclear localization of UBC9. This finding is consistent with the essential role of the N-terminal RanGTP binding domain for the binding and release of cargo. In the HeLa cells, the fusion protein encoded by the C-terminal fragment of rat IPO13 protein tagged with EYFP is confined primarily to cytoplasm, while the EYFPtagged full-length protein is distributed to both the nucleus and the cytoplasm (Tao et al., 2004) , suggesting that the TS-IPO13 and L-IPO13 proteins do function differently. It is likely that TS-IPO13 which lacks the RAN-GTP binding domain may act as a dominant negative regulator of the activity of L-IPO13 protein in the transportation and unloading of the cargo.
UBC9 is a cargo of IPO13 in the mouse germ cells
In the male germ cells, expression of the L-Ipo13 mRNA in the pachytene spermatocytes precedes the accumulation of UBC9 in the nucleus of the late-pachytene spermatocyte, when presumably the IPO13 is synthesized. UBC9 is a member of the ubiquitin-conjugating E2 enzymes, which regulate posttranscriptional modification or degradation of target proteins via the ubiquitin-dependent activity (reviewed by Melchior, 2000; Seeler and Dejean, 2003) . Loss of Ubc9 in the mouse embryo is associated with major chromosome condensation and segregation defects in blastocysts (Nacerddine et al., 2005) which is consistent with a critical role of UBC9 in regulating chromosome dynamics. UBC9 protein is a known cargo of human IPO13 and expression of human IPO13 alone is sufficient to drive nuclear accumulation of UBC9 in HeLa cells. This effect on UBC9 localization cannot be produced by Importin-β, -5, -7, or the α-β heterodimer or other forms of transportin (Mingot et al., 2001) . UBC9 is therefore the cargo that is specifically transported by IPO13. In contrast to other Importin-β family protein, IPO13 mediates import and export without any requirement to partner with Importin-α (Mingot et al., 2001) . The extent of knockdown of IPO13 in fetal ovary treated by siRNA (reagents #1 and #2) relative to the level of protein expression in the control with scrambled sequence siRNA (SS). Western analysis showed reduced amount of IPO13 in the siRNA-treated fetal ovary (a). The bands as detected by Coomassie brilliant blue (CBB) staining remained unchanged except for IPO13, suggesting that siRNA treatment did not have impact on the synthesis of other proteins, but specifically reduced the amount of IPO13 (b). One ovary (E15.5 + 3 days in vitro) was loaded for an each lane. Reduction of Ipo13 expression was also detected by RT-PCR in the knockdown ovary. (c) Ipo13 expression; (d) Hprt expression (control). (C) Ipo13 knockdown inhibits nuclear accumulation of UBC9 in oocytes. Nuclear accumulation of UBC9 is impeded in knockdown oocytes (arrow-heads in b and b′) but not in SS (arrows in a and a′). Scale bar: 5 μm. (D) Four different stages of meiotic prophase: Zygotene/Pachytene (Zy/ Pa), Mid-pachytene (M-Pa), Late-pachytene (L-Pa) and Pachytene-Diplotene (Pa/Di). Zy/Pa: irregularly shaped nuclei, and thick and long strands of SC (synaptonemal complex), M-Pa: spherical nuclei and decondensing chromatid with strands of SC, L-Pa: spherical and enlarged nuclei with decondenced chromatid with clumping of anti-SCP3 stained material, Pa/Di: large spherical nuclei and completely decondenced chromatid with one to two clumps of anti-SCP3 stained material. Scale bar: 5 μm. The tabulated results show the distribution of the siRNA-treated oocytes (identified by the expression of green Alexa488 fluorescence) to the four categories of oocytes at different stages of meiotic prophase I in E15.5 (in vivo) fetal ovary (beginning of the experiment) and E18.5 (in vivo) fetal ovary and in the cultured ovaries (E15.5 + 3 days in vitro; equivalent to E18.5) which were not transfected (not transfected) or treated with scrambled sequence (SS) siRNA and the two experimental groups treated by siRNA of siRNA#1 and siRNA#2. There are increases in proportion of M-Pa stage oocyte and corresponding decreases in L-Pa and Pa/Di stage oocytes in the two siRNA treatment groups (significant difference between SS and siRNA#1 or siRNA#2 at P < 0.05 by Chi-squared test). Three replicate experiments were performed for the not-transfected, SS, siRNA#1 and siRNA#2 groups and results of each experiment were obtained from three cultured specimens. Three samples of fetal ovaries each of E15.5 (in vivo) and E18.5 (in vivo) were scored for the number of germ cells at different meiotic stages. Numbers of oocytes (n) examined were: E15.5 (in vivo), n = 65; E18.5 (in vivo), n = 49; not transfected, n = 51; SS, n = 116: siRNA#1, n = 119; siRNA#2, n = 162.
Recently, human ubiquitin-conjugating class III E2 enzymes, UbcM2, UbcH6 and UBE2E2, were shown to be imported into nucleus by Importin-11 (IPO11). This is accomplished in an ubiquitin activation-dependent manner, such that only the ubiquitin-loaded form efficiently binds to IPO11 (Plafker et al., 2004) . However, in contrast to the interaction of IPO11 and UbcM2 (Plafker et al., 2004) , a robust interaction was detected between recombinant IPO13 and non-ubiquitin-loaded form of UBC9 (Mingot et al., 2001) . This may suggest that interaction of UBC9 and IPO13 is not dependent on the ubiquitin activation of UBC9.
In Drosophila, mutations of lesswright (lwr/Ubc9) suppress the non-disjunction and the cytological defects that affect spindle formation in the female meiotic germ cells, suggesting that LWR plays a role in the dissociation of homologous sequences in the heterochromatic regions of the chromosome at the end of meiotic prophase I (Apionishev et al., 2001) . In the mouse, UBC9 protein, which is localized at the synaptonemal complex, interacts with the Rad51 DNA recombination/repair enzyme and co-localizes with this enzyme in the synaptomenal complexes of late-pachytene spermatocytes (Kovalenko et al., 1996) . Recently, other cargoes carried by IPO13 have been identified: they include the NF-YB/NF-YC heterodimeric transcriptional activator (Kahle et al., 2005) and the pairedtype homeodomain transcriptional factor PAX6, PAX3 and CRX (Ploski et al., 2004) . In the mouse testis, orthologs of Importin-β (Importin-β1/Kpnb1) and Importin5 (Importin-β3/ Ranbp5/Kpnb3) are expressed in the spermatogenic cells (Anway et al., 2003; Loveland et al., 2005) in addition to Ipo13. The cargoes of other Importins that are expressed in the meiotic germ cells (Anway et al., 2003; Loveland et al., 2005) are not known.
In summary, we identified two transcripts of the mouse Ipo13 gene. L-Ipo13 is expressed in the PGCs and the pachytene stage germ cells in the fetal ovary and the adult testis, whereas TS-Ipo13 is only expressed in the spermatogenic cells of the postnatal testis. During the gametogenesis, L-Ipo13 expression is up-regulated at the pachytene stage in the prophase of meiosis I. The activity of the whole IPO13 protein, but not the truncated form that lacks the RanGTP binding domain, is essential for the nuclear localization of UBC9. In the female germ cells, IPO13 function in trafficking of cargo molecules, such as UBC9 and others yet unidentified cargoes that are present in the meiotic germ cells, may be required for the progression through the pachytene stage of prophase I of meiosis.
